Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) shares passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.09 and traded as low as $0.07. Nascent Biotech shares last traded at $0.07, with a volume of 103,490 shares changing hands.
Nascent Biotech Stock Down 21.3 %
The business’s 50-day moving average price is $0.09 and its 200-day moving average price is $0.12.
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Read More
- Five stocks we like better than Nascent Biotech
- Investing In Automotive Stocks
- RXO Shares Surge Following New Acquisition Deal
- How to Evaluate a Stock Before BuyingÂ
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- ESG Stocks, What Investors Should Know
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
